Tyramide Signal Amplification in In Situ Fluorescence Detection

Tyramide Signal Amplification (TSA) is one of the most representative enhancement strategies currently used in in situ fluorescence detection. Its core value is not simply to increase fluorescence intensity, but to convert local signals around low-abundance targets into a high-density, spatially confined, and relatively stable deposition layer while preserving spatial localization. In this way, the detectability of weakly expressed molecules can be significantly improved. TSA has notable methodological value for low-abundance antigens, highly autofluorescent samples, FFPE tissues, and sequential multiplex immunofluorescence systems.

Keywords: tyramide signal amplification; TSA; in situ fluorescence detection; HRP; multiplex immunofluorescence; FFPE; FISH

1 Technical Basis and Methodological Positioning

1.1 HRP-catalyzed deposition mechanism

(1) HRP localization

The TSA reaction first requires accurate introduction of horseradish peroxidase (HRP) to the vicinity of the target site. This is usually achieved through primary-secondary antibody systems, polymer-based HRP detection reagents, or biotin-streptavidin-HRP bridging systems. At this stage, the key issue is not merely whether antibody binding occurs, but whether HRP is restricted to the true target region. If HRP localization is inaccurate, subsequent deposition will amplify background at the same time.

(2) Tyramide activation

In the presence of hydrogen peroxide, HRP catalyzes oxidation of the tyramide substrate, generating a highly reactive intermediate with a very short lifetime and limited diffusion radius. Once formed, this intermediate preferentially reacts with nearby protein sites in tissues or cells around the HRP location. Therefore, TSA amplification does not make the entire slide uniformly brighter; rather, it locally brightens the target neighborhood.

(3) Local covalent deposition

Activated tyramide can covalently bind to electron-rich nearby sites such as tyrosine residues in neighboring proteins. If the tyramide molecule carries a fluorophore, deposition results in a high-density in situ fluorescent layer around the target. Unlike conventional fluorescent secondary antibodies, which rely on reversible binding, TSA generates a relatively fixed deposition signal and is therefore more suitable for sequential multi-round labeling.

 

Figure 1. Schematic Illustration of the Basic Principle of TSA-Based In Situ Fluorescence Detection

1.2 Nature of amplification and spatial characteristics

(1) Enzymatic turnover amplification

Enhancement in conventional indirect immunofluorescence essentially relies on one antibody complex carrying more fluorophores, whereas TSA relies on one HRP site catalyzing the deposition of multiple tyramide molecules. The former is binding-based amplification; the latter is enzyme-turnover amplification. This difference gives TSA an advantage in the detection of low-abundance targets.

(2) Spatially restricted amplification

A key feature of TSA-enhanced signals is that deposition occurs in the neighborhood of HRP rather than through global diffusion. Therefore, under appropriate reaction time and substrate concentration conditions, TSA can enhance weak signals while preserving histological boundaries and cellular structural information as much as possible.

(3) Signal retention capability

TSA deposits a label layer that remains on the sample rather than a fluorophore that remains on the antibody. This means that in sequential staining, even if antibodies from the current round are removed by heat retrieval or stripping, the signal deposited in the previous round is generally retained. This is the fundamental reason why TSA is suitable for multiplex in situ fluorescence detection.

1.3 Differences from conventional in situ fluorescence detection

(1) Difference from ordinary indirect immunofluorescence

Ordinary indirect immunofluorescence is suitable for medium- to high-abundance targets and structural marker detection. Its advantages are procedural simplicity and relatively controllable background. TSA is more suitable for weakly expressed targets, low-copy signals, and focally expressed sites, and its advantage lies in weak-signal enhancement rather than process simplification.

(2) Difference from conventional polymer amplification

Conventional polymer amplification still follows the principle that more detection molecules generate stronger signal. TSA, by contrast, relies on local catalytic deposition for enhancement. The former can improve overall detection efficiency, whereas the latter is more suitable for applications requiring high signal-to-noise ratio and multi-round sequential detection.

(3) Difference from chromogenic TSA

TSA can be used in both chromogenic and fluorescence-based systems. In in situ fluorescence detection, its main role is not to replace chromogenic methods, but to support multi-channel imaging, cellular colocalization analysis, and spatial expression stratification studies.

2 Major Application Scenarios in In Situ Fluorescence Detection

2.1 Detection of low-abundance antigens in FFPE tissues

(1) Localization of weakly expressed proteins

Because FFPE samples undergo fixation, dehydration, and paraffin embedding, they often show antigen masking, increased autofluorescence, and complex background. Many low-abundance proteins are difficult to visualize clearly and consistently by conventional immunofluorescence, whereas TSA can markedly improve their detectability in tissues through local deposition.

(2) Analysis of nuclear and focal markers

For nuclear proteins, transcription factors, weakly expressed membrane proteins, and focally distributed molecules, TSA can enhance local fluorescence signals without significantly compromising spatial resolution, thereby improving cell-level interpretation in tissue sections.

(3) Analysis of pathological samples with high background

In tumor tissues, inflamed tissues, and necrotic border zones, autofluorescence and nonspecific background are often prominent. In such cases, simply increasing the primary antibody concentration usually raises noise at the same time, whereas TSA is more effective in distinguishing true weak signals from complex background.

2.2 In situ fluorescence imaging in fixed cells

(1) Low-abundance intracellular targets

In fixed and permeabilized cells, TSA is suitable for detecting low-abundance nuclear regulatory molecules, weakly expressed receptors, and certain low-abundance mitochondrial or endoplasmic reticulum-associated proteins. In such cases, the significance of TSA lies in improving interpretive clarity rather than merely increasing image brightness.

(2) Combined use with conventional IF

In multi-target experiments, low-abundance targets may be enhanced by TSA, while highly expressed structural markers are still detected using ordinary fluorescent secondary antibodies. This allows sufficient enhancement of weak signals without requiring all labels to enter a more complex amplification workflow.

(3) Cellular colocalization analysis

At the cellular level, TSA is especially suitable for combined use with DAPI, organelle tracer dyes, and conventional immunofluorescence channels to analyze spatial relationships between low-abundance targets and nuclear, membrane, or organelle compartments.

2.3 In situ nucleic acid detection

(1) FISH signal enhancement

TSA is not limited to protein in situ detection; it can also be applied to in situ nucleic acid detection. For low-copy mRNA, weak hybridization signals, and DNA/RNA sites that are difficult to visualize directly, HRP-driven tyramide deposition can significantly enhance probe signal intensity.

(2) Optimization of weak-signal probe systems

In FISH systems, TSA is particularly suitable for low-expression transcripts, locally expressed RNAs, and samples in which signals are easily masked by tissue autofluorescence. Its advantage is not to alter probe specificity, but to improve the visualization efficiency of the original hybridization signal.

(3) Combined in situ analysis of proteins and nucleic acids

In spatial molecular analysis experiments, it is often necessary to observe a nucleic acid site together with related protein markers. Because TSA can serve as an enhancement method for both proteins and some nucleic acid assays, it is suitable for constructing a unified spatial analysis framework integrating proteins and nucleic acids.

2.4 Multiplex immunofluorescence

(1) Sequential multi-round labeling

The core advantage of TSA in multiplex in situ fluorescence is that after deposition is completed in each round, the antibodies from that round can be removed while the deposited fluorescent signal remains. Thus, multiple targets can be detected sequentially on the same tissue section.

(2) Reuse of same-species primary antibodies

In conventional multiplex immunofluorescence, combinations of primary antibodies from different host species are often a limiting factor in panel design. In sequential TSA systems, primary antibodies from the same species can, under certain conditions, be used in different rounds, thereby greatly increasing experimental design flexibility.

(3) FFPE multi-marker analysis

In tumor microenvironment studies, immune infiltration analysis, inflammation zonation, and spatial heterogeneity research, multiplex TSA systems can integrate multiple marker signals on the same tissue section while preserving histological context, making them particularly suitable for pathology and spatial expression studies.

Table 1 Typical application scenarios of TSA in in situ fluorescence detection

Application scenario	Main targets	Technical value	Key concerns
Low-abundance antigen detection in FFPE tissues	Nuclear proteins, weakly expressed membrane proteins, focal markers	Improves weak-signal visibility and spatial resolution	Antigen retrieval, endogenous peroxidase blocking
Immunofluorescence in fixed cells	Low-abundance organelle proteins, nuclear signaling molecules	Enhances imaging of low-abundance intracellular targets	Permeabilization conditions, background control
In situ nucleic acid detection	Low-copy mRNA or DNA loci	Improves probe signal and detection rate	Probe specificity, hybridization background
Multiplex immunofluorescence	Multi-marker analysis in FFPE tissues	Sequential staining, antibody stripping, reuse of same-species primary antibodies	Staining order, channel design, completeness of stripping

3 Experimental Workflow and Key Control Points

3.1 Sample pretreatment

(1) Fixation and retrieval conditions

For tissue samples, especially FFPE tissues, antigen retrieval is always the prerequisite for TSA success. TSA does not compensate for poor pretreatment; instead, it amplifies problems arising from inadequate antigen exposure, background exposure, or tissue damage. Therefore, before establishing a TSA system, reliable conditions for fixation, deparaffinization, retrieval, and permeabilization must first be established.

(2) Blocking endogenous peroxidase

Because TSA depends on HRP catalysis, insufficient blocking of endogenous peroxidase can easily lead to diffuse background deposition. This issue is particularly important in tissues rich in blood components, inflammatory cells, or endogenous oxidase activity.

(3) Control of tissue autofluorescence

In tissue samples, autofluorescence is often associated with the fixation method, sample origin, and pigment deposition. Although TSA can improve signal-to-noise ratio, it cannot replace autofluorescence control. For high-background samples, background quenching or multispectral separation strategies remain necessary.

3.2 Antibody systems and HRP introduction

(1) Priority of primary antibody optimization

TSA does not mean that antibody specificity validation can be ignored. If the primary antibody itself shows obvious nonspecific binding, TSA will merely amplify false-positive signals. Therefore, optimization of primary antibody titer, blocking conditions, and negative controls should first be completed under single-marker conditions.

(2) Choice of HRP detection system

TSA commonly uses HRP-labeled secondary antibodies or polymer-based HRP systems. Different systems differ in local amplification efficiency, penetration, and background characteristics, so the appropriate solution should be selected according to sample type, target abundance, and multiplex design requirements.

(3) Matching HRP localization strategy to the detection objective

If a biotinylated antibody or probe system is used, HRP can be introduced through avidin-HRP or streptavidin-HRP. If a conventional primary antibody system is used, HRP-labeled secondary antibodies are more commonly used. The HRP introduction strategy must be compatible with the entire detection framework rather than judged only by whether one step can produce signal.

3.3 Tyramide deposition reaction

(1) Substrate concentration

If the tyramide substrate concentration is too low, amplification will be insufficient; if it is too high, local deposition may become excessive, raising background and causing boundary spreading. Therefore, substrate concentration should not be applied mechanically as a fixed value, but optimized gradually based on target abundance and sample background.

(2) Reaction time

Tyramide incubation time is one of the most sensitive parameters. If too short, weak-signal enhancement is insufficient; if too long, local deposition spreads into surrounding regions, resulting in increased granularity and reduced spatial resolution. For low-abundance targets, an appropriate balance must be found between visibility and over-deposition.

(3) Termination of reaction

Once the desired signal level is reached, the reaction should be stopped promptly. Continued exposure to the HRP/hydrogen peroxide/substrate system allows deposition to continue, ultimately affecting target boundaries and histological interpretation.

3.4 Counterstaining and imaging

(1) Nuclear counterstaining

TSA produces enhanced local signals, but localization of cellular and tissue structure still depends on nuclear counterstaining and other morphological references. Nuclear dyes such as DAPI provide a basic coordinate framework for subsequent cell counting and regional interpretation.

(2) Exposure settings

For TSA samples, imaging should not simply follow conventional immunofluorescence exposure habits. If exposure is too strong, enhanced signals are easily saturated, reducing dynamic range and impairing interpretation of weak-to-strong expression gradients.

(3) Uniform image acquisition parameters

If the experiment includes comparisons across groups or across rounds, acquisition parameters should be kept as consistent as possible. Otherwise, differences in image brightness may reflect imaging conditions rather than biology, reducing comparability.

4 Design Logic for Multiplex TSA

4.1 Staining order

(1) Weak targets first

In multiplex TSA, low-abundance and hardest-to-detect targets should generally be placed in earlier rounds, whereas highly abundant strong-signal targets should be placed in later rounds. This makes it easier for weak signals to first establish a stable deposition layer and reduces the dominance of strong signals in later interpretation.

(2) Hierarchical arrangement of functional and structural markers

In complex panels, it is often preferable to first complete TSA labeling of low-expression functional markers and then to stain highly expressed structural markers or cell identity markers. This helps reduce channel dominance and image suppression effects.

4.2 Antibody stripping and signal retention

(1) Completeness of stripping

In sequential multiplex systems, after each deposition round the antibodies from that round must be removed by heat-induced antigen retrieval or another stripping strategy. If stripping is incomplete, cross-round carryover and false colocalization will appear in later rounds.

(2) Signal retention

The technical advantage of TSA lies precisely in the retention of deposited signals after antibody stripping. If signals from earlier rounds are obviously weakened during the experiment, this usually indicates incompatibility between stripping conditions, mounting procedures, or imaging workflow.

4.3 Channel and spectral allocation

(1) Avoidance of spectral overlap

In multiplex in situ fluorescence, spectral overlap between different tyramide fluorophore channels should be minimized as much as possible. This is especially important when strong and weak targets coexist, because leakage from a strong-signal channel into a weak-signal channel significantly reduces interpretive power.

(2) Matching signal strength to fluorophore channel

More sensitive fluorescence channels are better suited to weakly expressed targets, whereas channels with relatively higher background or lower sensitivity are more suitable for highly expressed targets. If this allocation is unbalanced, staining may technically succeed, but the resulting images may still be unsuitable for quantification or spatial comparison.

Table 2 Key variables and common deviations in TSA in situ fluorescence detection

Variable	Manifestation of deviation	Common cause	Priority for optimization
Antigen retrieval	Weak or unstable signal	Insufficient or excessive retrieval	Optimize retrieval conditions first
Peroxidase blocking	Diffuse background increase	Endogenous enzyme activity not adequately suppressed	Strengthen blocking step
Primary antibody concentration	False positivity or blurred boundaries	Excessive primary antibody nonspecificity	Lower concentration and redesign controls
Tyramide incubation time	Over-deposition, increased granularity	Excessive substrate reaction time	Shorten reaction time
Round design	False colocalization, weak-signal suppression	Unreasonable sequence, incomplete stripping	Place weak targets first and verify stripping
Channel assignment	Crosstalk, reduced resolution	Spectral overlap or mismatch of signal strength and channel	Reassign fluorescence channels

5 Common Problems and Interpretation Points

5.1 Elevated background

(1) Sources of background

The most common sources of TSA background are insufficient endogenous peroxidase blocking, nonspecific binding of the primary or secondary antibody, and excessively long tyramide deposition time. Compared with conventional immunofluorescence, TSA background more often appears as enhanced deposition-type signal, which is difficult to correct effectively by image processing once formed.

(2) Optimization strategy

A more rational strategy is to suppress background first rather than simply reduce exposure. Specifically, one should sequentially check blocking conditions, antibody titer, HRP system, and deposition time, and use negative controls to localize the source of the problem.

5.2 Insufficient signal

(1) Do not mechanically extend the reaction

If signal remains weak, the problem may stem from insufficient antigen retrieval, low primary antibody affinity, inadequate HRP system efficiency, or extremely low target abundance. In such cases, simply prolonging the tyramide reaction often increases background at the same time.

(2) Optimization order

A more rational optimization order is usually: first optimize sample pretreatment, then optimize the primary antibody, then optimize the HRP system, and only then fine-tune tyramide incubation time and reaction termination conditions.

5.3 False colocalization

(1) Residual antibodies

In multiplex TSA, if antibodies from a previous round are not completely removed, later rounds may show false colocalization or cross-round background. Therefore, verification of stripping is not optional; it is a prerequisite for the validity of multiplex experiments.

(2) Boundary broadening

If deposition in one round is too strong, even molecules that are not truly colocalized may appear overlapping in images because of signal spread. Therefore, image interpretation should consider not only intensity, but also boundaries and consistency with tissue structure.

6 Application Recommendations

6.1 Single-marker optimization first

Before establishing a multiplex TSA panel, each marker should first be optimized individually, including pretreatment conditions, primary antibody concentration, HRP system, and tyramide deposition time. Only when single-marker parameters are stable can a multiplex panel achieve reproducibility.

6.2 Focus on signal-to-noise ratio rather than brightness alone

The greatest value of TSA lies in improving the visibility of low-abundance targets while preserving accurate spatial localization. Therefore, optimization should prioritize signal-to-noise ratio, fidelity of tissue structure, and local boundary preservation, rather than simply maximizing brightness.

6.3 Application boundaries

TSA is most suitable for three types of tasks: enhancement of low-abundance targets, identification of weak signals in high-background samples, and sequential multiplex fluorescence labeling in FFPE tissues. If the goal is only routine colocalization of highly expressed proteins, conventional immunofluorescence is usually sufficient and there is no need to introduce a more complex workflow.

7 Aladdin-Related Products

Table 3 Basic Chemical Reagents for TSA-Based In Situ Fluorescence Detection

Name	CAS No.	Applicable step	Main use
Tyramine	51-67-2	Substrate system	Parent substrate for TSA reactions; suitable for configuring tyramide deposition systems and method development
Tyramine hydrochloride	60-19-5	Substrate system	Better solubility; suitable for preparing tyramide working solutions
Hydrogen peroxide	7722-84-1	HRP catalytic reaction	Oxidative substrate required for HRP catalysis to drive tyramide activation and deposition
Triton X-100	9002-93-1	Permeabilization	Used for permeabilization of fixed cells or some tissue samples
Tween 20	9005-64-5	Wash system	Used to prepare TBST or PBST, reduce nonspecific background, and improve washing efficiency
DAPI	28718-90-3	Nuclear counterstaining	Used for nuclear counterstaining and tissue structure localization
Citric acid	77-92-9	Antigen retrieval	Commonly used to prepare low-pH antigen retrieval solutions
Trisodium citrate dihydrate	6132-04-3	Antigen retrieval	Used together with citric acid to prepare citrate retrieval buffer
Glycine	56-40-6	Buffer/termination	Can be used in some systems for quenching, termination, or buffer adjustment

Table 4 Functional Detection Products for TSA-Based In Situ Fluorescence Detection

Catalog No.	Name	Grade and Purity	Corresponding step	Suitable research direction / use
R1511497	Ready-to-use LumiDye™ 540 Tyramide (200×)	BioReagent, ready-to-use, Biological Stain, for fluorescence analysis, for microscopy, for ELISA, Suitable for Immunohistochemistry(IHC), Suitable for Immunofluorescence(IF)	Core fluorescent deposition substrate for TSA	Suitable for the core deposition step in in situ fluorescence TSA, including weak antigen enhancement, tissue-section in situ fluorescence detection, and sequential multiplex IF design
H597642	Horseradish Peroxidase (HRP)	EnzymoPure™, ≥150 U/mg powder, Rz≥1.5	Core catalytic enzyme for HRP	Suitable for establishing TSA reaction systems and validating HRP activity and tyramide deposition methodology
P105525	Horseradish Peroxidase (HRP)	EnzymoPure™, >200 U/mg, RZ 2-4	Core catalytic enzyme for HRP	Suitable for optimizing HRP-catalyzed reactions in in situ fluorescence TSA, especially in systems requiring high activity and purity
P105526	Horseradish Peroxidase (HRP)	Biologically active, ActiBioPure™, natural, high performance, EnzymoPure™, from horseradish; ≥160 U/mg, Rz≥2.0	Core catalytic enzyme for HRP	Suitable for building tissue- and cell-level TSA systems and establishing high-activity HRP-catalyzed deposition workflows
P105528	Horseradish Peroxidase (HRP)	EnzymoPure™, ≥250 U/mg, Rz≥3	Core catalytic enzyme for HRP	Suitable for optimizing TSA methods requiring higher catalytic efficiency and stronger signal enhancement
P578793	Horseradish Peroxidase (HRP)	Biologically active, ActiBioPure™, natural, high performance, EnzymoPure™, from horseradish; ≥100 U/mg enzyme powder; RZ≥1	Core catalytic enzyme for HRP	Suitable for routine TSA condition exploration and establishment of basic HRP catalytic systems
R1507819	Horseradish Peroxidase (HRP)	Biologically active, recombinant, ActiBioPure™, high performance, EnzymoPure™, ≥150 U/mg enzyme powder, Rz ≥2; expressed in Nicotiana benthamiana	Recombinant HRP catalytic enzyme	Suitable for TSA experiments sensitive to variability in natural-source HRP, helping improve batch-to-batch consistency
R1507818	Horseradish Peroxidase (HRP)	Biologically active, recombinant, ActiBioPure™, high performance, EnzymoPure™, ≥250 U/mg enzyme powder, Rz ≥3; expressed in Nicotiana benthamiana	Recombinant HRP catalytic enzyme	Suitable for high-sensitivity in situ fluorescence TSA systems and high-demand methodological development
H1508159	Horseradish Peroxidase (HRP)	Biologically active, ActiBioPure™, natural, high performance, EnzymoPure™, ≥300 U/mg enzyme powder, Rz≥3; from horseradish	High-purity HRP catalytic enzyme	Suitable for TSA enhancement experiments requiring high catalytic activity and deposition efficiency
H1507817	Horseradish Peroxidase (HRP)	Biologically active, recombinant, ActiBioPure™, high performance, EnzymoPure™, ≥150 U/mg enzyme powder, Rz ≥2.0	Recombinant HRP catalytic enzyme	Suitable for establishing standardized workflows for in situ fluorescence TSA
P298979	Peroxidase from horseradish（HRP）	EnzymoPure™, ≥180 U/mg powder, Rz≥2.0	Core catalytic enzyme for HRP	Suitable for establishing routine TSA deposition systems and validating HRP performance
A638716	Aladdin™ Avidin HRP	—	HRP introduction / biotin-bridging system	Suitable for biotinylated probe or biotinylated antibody systems in TSA in situ fluorescence amplification, allowing HRP to be bridged to the target site
A638862	Avidin, HRP conjugate	—	HRP introduction / biotin-bridging system	Suitable for biotin-avidin-HRP strategies in in situ fluorescence detection of tissue or cellular targets
np156148	SA-HRP	High performance, azide-free, 1.0 mg/mL	HRP introduction / biotin-bridging system	Suitable for TSA in situ fluorescence enhancement in biotinylated probe, biotinylated secondary antibody, or nucleic acid probe systems
H1454426	HRP-Streptavidin	—	HRP introduction / biotin-bridging system	Suitable for biotin-dependent HRP localization and subsequent tyramide deposition amplification
S292620	SA-HRP (HRP-labeled Streptavidin)	500 U/mL	HRP introduction / biotin-bridging system	Suitable for tissue-section or cellular TSA fluorescence designs using biotinylated antibodies/probes
rp188518	NeutrAvidin Protein (HRP)	ExactAb™, validated, 1.0 mg/mL	Low-background HRP bridging system	Suitable for in situ fluorescence experiments that are highly sensitive to nonspecific background and can reduce nonspecific binding compared with traditional avidin systems
Ab176443	Goat Anti-Rabbit IgG H&L (HRP)	ExactAb™, high performance, validated, azide-free	HRP-labeled secondary antibody	Suitable for rabbit primary antibody-based TSA in situ fluorescence detection, introducing HRP near the target antigen
Ab170144	Goat Anti-Rabbit IgG H&L (HRP)	ExactAb™, azide-free, validated, high performance, pre-adsorbed, 1.0 mg/mL	HRP-labeled secondary antibody	Suitable for rabbit primary antibody TSA experiments with stringent background control; the pre-adsorbed design is advantageous in complex samples
Ab179001	Goat Anti-Mouse IgG H&L (HRP)	ExactAb™, high performance, validated, azide-free, 1.0 mg/mL	HRP-labeled secondary antibody	Suitable for TSA in situ fluorescence detection using mouse primary antibodies
Ab138040	Goat Anti-Mouse IgG H&L (HRP)	ExactAb™, high performance, validated, 1 mg/mL	HRP-labeled secondary antibody	Suitable for routine TSA amplification workflows using mouse primary antibodies
Ab156255	Goat Anti-Mouse IgG H&L (HRP)	ExactAb™, azide-free, validated, high performance, pre-adsorbed, 1.0 mg/mL	Low-background HRP-labeled secondary antibody	Suitable for mouse primary antibody TSA experiments in complex tissues, low-abundance targets, and high-background samples
Ab170181	Goat Anti-Chicken IgY H&L (HRP)	ExactAb™, high performance, validated, azide-free, 1.0 mg/mL	HRP-labeled secondary antibody	Suitable for in situ fluorescence TSA experiments using chicken primary antibodies
Ab137759	Goat Anti-Chicken IgY H&L (HRP)	ExactAb™, high performance, validated, 1 mg/mL	HRP-labeled secondary antibody	Suitable for tissue- or cell-based TSA enhancement experiments involving chicken antibodies
Ab175835	Goat Anti-Human IgG (HRP)	ExactAb™, high performance, validated, azide-free, 1.0 mg/mL	HRP-labeled secondary antibody	Suitable for TSA amplification designs in human IgG detection systems
Ab137905	Goat Anti-Human IgG H&L (HRP)	ExactAb™, high performance, validated, 1 mg/mL	HRP-labeled secondary antibody	Suitable for in situ fluorescence TSA experiments involving human-source antibodies
Ab141534	Rabbit Anti-Goat IgG H&L (HRP)	ExactAb™, high performance, validated, 1.0 mg/mL	HRP-labeled secondary antibody	Suitable for TSA amplification designs using goat primary antibodies
Ab223351	Rabbit Anti-Goat IgG H&L (HRP)	ExactAb™, validated, azide-free, 1.0 mg/mL	HRP-labeled secondary antibody	Suitable for goat primary antibody TSA experiments requiring azide-free conditions
Ab176437	Rabbit Anti-Mouse IgG (HRP)	ExactAb™, high performance, validated, azide-free, 1.0 mg/mL	HRP-labeled secondary antibody	Suitable as an alternative HRP introduction strategy in mouse antibody-based systems
Ab141622	Rabbit Anti-Mouse IgG H&L (HRP)	ExactAb™, high performance, validated, 1.0 mg/mL	HRP-labeled secondary antibody	Suitable for in situ fluorescence TSA amplification using mouse primary antibodies
Ab139791	Mouse Anti-Human IgG H&L (HRP)	Carrier-free, ExactAb™, azide-free, validated, see COA	HRP-labeled secondary antibody	Suitable for HRP introduction in human IgG detection backgrounds
H598247	HRP antibody labeling kits	—	Antibody-HRP conjugation	Suitable for conjugating self-prepared antibodies to HRP for customized TSA in situ fluorescence systems
M1508746	HRP Conjugation Kit (SMCC Activated)	BioReagent	Antibody-HRP conjugation	Suitable for coupling antibodies or proteins to HRP via SMCC for self-built TSA detection workflows
H1506714	HRP Conjugation Kit (SMCC Activated)	BioReagent	Antibody-HRP conjugation	Suitable for HRP conjugation method development and customized antibody labeling
P1506712	HRP Conjugation Kit (Periodate Activated)	BioReagent	Antibody-HRP conjugation	Suitable for HRP conjugation by the sodium periodate method in customized TSA in situ fluorescence detection
P1508744	HRP Conjugation Kit (Periodate Activated)	BioReagent	Antibody-HRP conjugation	Suitable for comparing HRP conjugation strategies and customized antibody labeling
M1491737	LumiDye™ SMCC Activated HRP (SMCC-HRP)	BioReagent	Activated HRP conjugation module	Suitable for constructing customized HRP-conjugated antibodies or HRP probes for TSA method development

The advantages of TSA in in situ fluorescence detection can ultimately be summarized at three levels: weak-signal enhancement, spatially confined deposition, and compatibility with sequential multiplex labeling. More effective use of this technology depends not on treating it as a simple additional enhancement step after conventional immunofluorescence, but on understanding it as a complete methodological system built around pretreatment, HRP localization, tyramide deposition, staining order design, and result interpretation.

For more related articles, please see below:

[1] Cyanine 3 Tyramide (Cy3 Tyramide): Principles, Applications, and Experimental Selection Guide for Tyramide Signal Amplification (TSA)